CD27 Expression Identified as Key Marker for Monitoring Treg Therapy Efficacy

Research has identified CD27 expression as a potential biomarker for monitoring the therapeutic efficacy of regulatory T cell (Treg) induction in clinical trials. The findings, published in Frontiers in Immunology, define a population of induced Tregs marked by elevated CD27 expression that correlates with immune suppression capacity.

In the study, researchers induced Tregs in vitro from naive CD4 T cells using tolerogenic dendritic cells (tolDCs) and compared their phenotypes to effector T cells induced by pro-inflammatory dendritic cells. Clustering analysis revealed three distinct groups distinguishing induced Treg cultures from effector T cells, all marked by high CD27 expression, of which two clusters had a memory-like phenotype and expressed regulatory markers TIGIT, PD-1 and CD38.

The kinetics of CD27 expression showed that naive T cells increase CD27 expression during their differentiation into memory-like Tregs, whereas CD27 is lost during differentiation into pro-inflammatory effector T cells. The presence of CD27 and TIGIT-expressing memory-like Tregs positively correlated with the inhibition capacity of the induced Treg lines in vitro.

Increased ratios of these Tregs over effector T cells in vivo following vaccination of type 1 diabetes patients with tolerogenic DCs pulsed with islet autoantigen correlated with increased islet-specific immune regulation ex vivo. CD27 expression marks superior suppressive naturally occurring Tregs (nTregs), while in cancer settings this has been shown to be a prognostic marker for tumor progression.

The research comes amid growing interest in Treg-based therapies for precision tolerance medicine. A separate lead article in Frontiers in Science describes Tregs as adaptive, tissue-specialized regulators that maintain immune tolerance and tissue homeostasis. Dysregulated inflammation underlies many diseases, positioning Treg-based tolerance restoration as a therapeutic strategy beyond traditional transplant and autoimmune indications.

Early clinical studies have established a foundation of safety and feasibility for Treg therapies, while next-generation approaches aim to improve specificity, persistence, stability, and scalability. Chimeric antigen receptor Tregs show early clinical promise in autoimmunity and transplantation, including target-site enrichment and phenotypic stability.

The field is moving beyond early polyclonal Treg therapies toward more targeted approaches, including antigen-specific, engineered, and potentially off-the-shelf or in vivo strategies. Researchers emphasize that biologically informed Treg trials must move beyond safety, matching products and trial designs to the indication to demonstrate tissue localization, stability, and immune reprogramming.